

Remarks/Arguments
Status of the Application

Claims 1-10, 15, and 18 have been canceled; claims 11, 14, and 19 amended; claims 17 and 20 withdrawn; and claims 21 and 22 added so that claims 11-14, 16, 19, and 21-22 are pending.

Applicants have further amended the claims presented in response to the Non-final Office Action mailed February 18, 2008 to delete the non-elected subject matter therefrom, as well as add another new claim 22.

Claim 11 has been amended to remove formula (a) from the definition of A. Claim 11 has been further amended to accommodate the deletion of formula (a) as well as the C2 to 8 alkenyl and C2 to 8 alkynyl groups therefrom.

Claim 14 has been amended to retain the alkoxy group deleted from Claim 14 in the response to the Non-final Office Action submitted May 15, 2008. Specifically, Applicants have amended the C1 to 6 alkoxy group of claim 14 to a C1 to 4 alkoxy, which finds antecedent basis in claim 11.

Claim 19 has been amended to place it in proper U.S. format.

Claim 21 has been amended to delete the compounds directed to the non-elected subject matter of Group II as identified in the Restriction Requirement mailed November 14, 2007.

Any amendments made herein have been made without prejudice to Applicants' right to prosecute any cancelled subject matter in a timely filed continuation/divisional application.

Rejoinder

Applicants point out that following the amendments submitted herewith, Groups I, III and V set forth in the Restriction Requirement mailed November 14, 2007 are related as product and process for making/using. As Applicants elected to pursue the Group I product claims, Applicants respectfully request in accordance with MPEP § 821.04 the Office rejoin the withdrawn process claims when the product claim from which such process claims depend is found allowable.

SUMMARY

In view of the foregoing amendments and remarks, Applicants respectfully submit the application is in condition for allowance and respectfully solicit a Notice of Allowance. In order to expedite disposition of this case, the Office is invited to contact Applicants' representative at the

telephone number below to resolve any remaining issues. Although Applicants believe no fees other than those that may accompany this response are due, the Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 101219-1P US.

Respectfully submitted,

/Jacqueline M. Cohen/

Name: Jacqueline M. Cohen
Dated: August 18, 2008
Reg. No.: 51,574
Phone No.: 302-885-4269
Intellectual Property, Patents,
AstraZeneca
1800 Concord Pike
Wilmington, DE-19850-5437